Establishment and validation of a new semi-chronic dextran sulfate sodium-induced model of colitis in mice

International Immunopharmacology

Volumn 15, Issue 1, 2013, Pages 23-29

  Sha, Takukyu ^a   Igaki, Keiko ^a   Yamasaki, Masashi ^a   Watanabe, Takeshi ^a   Tsuchimori, Noboru ^a  

^a TAKEDA PHARMACEUTICAL COMPANY LIMITED   (Japan)

Author keywords

Anti IL 12 23p40; Anti TNF ; Dextran sulfate sodium; Mouse colitis

Indexed keywords

DEXTRAN SULFATE; DRINKING WATER; INTERLEUKIN 12P35; PREDNISOLONE; SALAZOSULFAPYRIDINE; TACROLIMUS; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; INTERLEUKIN 12 ANTIBODY; INTERLEUKIN 12P40 ANTIBODY; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CELL INFILTRATION; CELL LOSS; COLITIS; CONTROLLED STUDY; CYTOKINE PRODUCTION; DESCENDING COLON; DIARRHEA; DISEASE ACTIVITY; DISEASE ASSOCIATION; DRUG EFFICACY; FEMALE; HISTOLOGY; INFLAMMATORY CELL; INTESTINE CRYPT; MEDIATOR RELEASE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RECTUM HEMORRHAGE; VALIDATION STUDY; WEIGHT REDUCTION; CRYPT CELL; DRUG INDUSTRY; ULCERATIVE COLITIS;

EID: 84872315026     PISSN: 15675769     EISSN: 18781705     Source Type: Journal    
DOI: 10.1016/j.intimp.2012.10.022     Document Type: Article

References (36)

1. Xavier RJ, Podolsky DK. Unravelling the pathogenesis of inflammatory bowel disease. Nature 2007;448:427-34.
2. Sanchez-Munoz F, Dominguez-Lopez A, Yamamoto-Furusho JK. Role of cytokines in inflammatory bower disease. World J Gastroenterol 2008;14:4280-8.
3. Neuman MG Immune dysfunction in inflammatory bower disease. Transl Res 2007;149:173-86.
4. Olsen T, Goll R, Cui G, Husebekk A, Vonen B, Birketvedt GS, et al. Tissue levels of tumor necrosis factor-alpha correlates with grade of inflammation in untreated ulcerative colitis. Scand J Gastroenterol 2007;42:1312-20.
5. Nielsen OH, Kirman I, Rudiger N, Hendel J, Vainer B. Upregulation of interleukin-12 and -17 in active inflammatory bowel disease. Scand J Gastroenterol 2003;38:180-5.
6. Olsen T, Rismo R, Cui G, Goll R, Christiansen I, Florholmen J. TH1 and TH17 interactions in untreated inflamed mucosa of inflammatory bowel disease, and their potential to mediate the inflammation. Cytokine 2011;56:633-40.
7. Leon AJ, Gomez E, Garrote JA, Bernardo D, Barrera A, Marcos JL, et al. High levels of proinflammatory cytokines, but not of markers of tissue injury, in unaffected intestinal areas from patients with IBD. Mediators Inflamm 2009;2009:1-10.
8. Hoentjen F, Sakuraba A, Hanauer S. Update on the management of ulcerative colitis. Curr Gastroenterol Rep 2011;13:475-85.
9. Rosenberg LN, Peppercorn MA. Efficacy and safety of drugs for ulcerative colitis. Expert Opin Drug Saf 2010;9:1-20.
10. Nishioka C, Aoyama N, Maekawa S, Shirasaka D, Nakahara T, Tamura T, et al. Leukocytapheresis therapy for steroid-naïve patients with active ulcerative colitis: its clinical efficacy and adverse effects compared with those of conventional steroid therapy. J Gastroenterol Hepatol 2005;20:1567-71.
11. Yamamoto S, Nakase H, Mikami S, Inoue S, Yoshino T, Takeda Y, et al. Long-term effect of tacrolimus therapy in patients with refractory ulcerative colitis. Aliment Pharmacol Ther 2008;28:589-97.
12. Rutgeerts P, Sandborn WJ, Feagan BG, Reinisch W, Olson A, Johanns J, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005;353:2462-76.
13. Sandborn WJ, Feagan BG, Fedorak RN, Scherl E, Fleisher MR, Katz S, et al. A randomized trial of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease. Gastroenterology 2008;135:1130-41.
14. Xu CT, Meng SY, Pan BR. Drug therapy for ulcerative colitis. World J Gastroenterol 2004;10:2311-7.
15. Bernstein CN, Fried M, Krabshuis JH, Cohen H, Eliakim R, Fedail S, et al. World Gastroenterology Organization practice guidelines for the diagnosis and management of IBD in 2010. Inflamm Bowel Dis 2010;16:112-24.
16. Cosnes J, Gower-Rousseau C, Seksik P, Cortot A. Epidemiology and natural history of inflammatory bower diseases. Gastroenterology 2011;140:1785-94.
17. Yan Y, Kolachala V, Dalmasso G, Nguyen H, Laroui H, Sitaraman SV, et al. Temporal and spatial analysis of clinical and molecular parameters in dextran sodium sulfate induced colitis. PLoS One 2009;4:1-8.
18. Perse M, Cerar A. Dextran sodium sulphate colitis mouse model: traps and tricks. J Biomed Biotechnol 2012;2012:718617.
19. Hall LJ, Faivre E, Quinlan A, Shanahan F, Nally K, Melgar S. Induction and activation of adaptive immune populations during acute and chronic phases of a murine model of experimental colitis. Dig Dis Sci 2011;56:79-89.
20. Maxwell JR, Viney JL. Overview of mouse models of inflammatory bowel disease and their use in drug discovery. Curr Protoc Pharmacol 2009;47:5.57.1-5.57.19.
21. Siegmund B, Rieder F, Albrich S, Wolf K, Bidlingmaier C, Firestein GS, et al. Adenosine kinase inhibitor GP515 improves experimental colitis in mice. J Pharmacol Exp Ther 2001;296:99-105.
22. Matthes H, Krummenerl T, Giensch M, Wolff C, Schulze J. Clinical trial: probiotic treatment of acute distal ulcerative colitis with rectally administered Escherichia coli Nissle 1917 (EcN). BMC Complement Altern Med 2010;10:13-20.
23. Ogata H, Kato J, Hirai F, Hida N, Matsui T, Matsumoto T, et al. Double-blind, placebo-controlled trial of oral tacrolimus (FK506) in the management of hospitalized patients with steroid-refractory ulcerative colitis. Inflamm Bowel Dis 2012;18:803-8.
24. Fuss IJ Cytokine network in inflammatory bowel disease. Curr Drug Targets Inflamm Allergy 2003;2:101-12.
25. Li CQ, Xie XJ, Yu T, Gu XM, Zuo XL, Zhou CJ, et al. Classification of inflammation activity in ulcerative colitis by confocal laser endomicroscopy. Am J Gastroenterol 2010;105:1391-6.
26. Osada T, Ohkusa T, Okayasu I, Yoshida T, Hirai S, Beppu K, et al. Correlations among total colonoscopic findings, clinical symptoms, and laboratory markers in ulcerative colitis. J Gastroenterol Hepatol 2008;23(Suppl. 2):S262-7.
27. Kanagarajan N, Nam JH, Noah ZA, Murthy S. Disease modifying effect of statins in dextran sulfate sodium model of mouse colitis. Inflamm Res 2008;57:34-8.
28. Murch SH, Braegger CP, Walker-Smith JA, MacDonald TT. Location of tumour necrosis factor alpha by immunohistochemistry in chronic inflammatory bowel disease. Gut 1993;34:1705-9.
29. Komatsu M, Kobayashi D, Saito K, Furuya D, Yagihashi A, Araake H, et al. Tumor necrosis factor-alpha in serum of patients with inflammatory bowel disease as measured by a highly sensitive immuno-PCR. Clin Chem 2001;47:1297-301.
30. Reinisch W, Sandborn WJ, Rutgeerts P, Feagan BG, Rachmilewitz D, Hanauer SB, et al. Long-term infliximab maintenance therapy for ulcerative colitis: the ACT-1 and -2 extension studies. Inflamm Bowel Dis 2012;18:201-11.
31. Qiu W, Wu B, Wang X, Buchanan ME, Regueiro MD, Hartman DJ, et al. PUMA-mediated intestinal epithelial apoptosis contributes to ulcerative colitis in humans and mice. J Clin Invest 2011;121:1722-32.
32. Verstege MI, te Velde AA, Hommes DW. Apoptosis as a therapeutic paradigm in inflammatory bowel diseases. Acta Gastroenterol Belg 2006;69:406-12.
33. Melgar S, Karlsson L, Rehnstrom E, Karlsson A, Utkovic H, Jansson L, et al. Validation of murine dextran sulfate sodium-induced colitis using four therapeutic agents for human inflammatory bowel disease. Int Immunopharmacol 2008;8:836-44.
34. Brown JB, Cheresh P, Zhang Z, Ryu H, Managlia E, Barrett TA. P-selectin glycoprotein ligand-1 is needed for sequential recruitment of T-helper 1 (Th1) and local generation of Th17 T cells in dextran sodium sulfate (DSS) colitis. Inflamm Bowel Dis 2012;18:323-32.
35. Camuesco D, Rodriguez-Cabezas ME, Garrido-Mesa N, Cueto-Sola M, Bailon E, Comalada M, et al. The intestinal anti-inflammatory effect of dersalazine sodium is related to a down-regulation in IL-17 production in experimental models of rodent colitis. Br J Pharmacol 2012;165:729-40.
36. Pang YH, Zheng CQ, Yang XZ, Zhang WJ. Increased expression and activation of IL-12-induced Stat4 signaling in the mucosa of ulcerative colitis patients. Cell Immunol 2007;248:115-20.